$9.07
0.98%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US61225M1027
Symbol
GLUE

Monte Rosa Therapeutics Inc Stock price

$9.07
-1.59 14.92% 1M
-8.94 49.64% 6M
-6.61 42.16% YTD
-4.54 33.36% 1Y
+5.72 170.75% 3Y
-12.87 58.66% 5Y
-12.11 57.18% 10Y
-12.11 57.18% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.09 0.98%
ISIN
US61225M1027
Symbol
GLUE
Industry

Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$775.0m
Enterprise Value
$153.9m
Net debt
positive
Cash
$621.1m
Shares outstanding
85.2m
Valuation
P/E
negative
P/S | estimate
27.0 | 8.2
EV/Sales | estimate
5.4 | 1.6
EV/FCF | ex SBC
negative | negative
P/B
1.6
Financial Health
Equity Ratio
52.0%
Return on Equity
-16.6%
ROCE
-28.8%
ROIC
-438.0%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$20.6m | 71.7%
SBC as % of FCF
-
SBC Growth 1Y
8.7%
Share Count Growth 1Y
38.1%
Shareholder Yield
-38.1%
Financials
Revenue | estimate
$28.7m | $94.0m
EBITDA
$-173.7m
EBIT
$-181.9m
Net Income
$-161.1m
Free Cash Flow | ex SBC
$-32.1m | $-52.7m
Growth
Revenue | estimate
-83.9% | -24.0%
EBITDA
-845.6%
EBIT
-1,315.7%
Net Income
-766.6%
Free Cash Flow
-234.5%
Margin
Gross
-
EBITDA
-604.8%
EBIT
-633.0%
Net
-560.9%
Free Cash Flow | ex SBC
-111.7% | -183.4%
More
EPS
$-1.6
FCF per Share
$-0.4
Short interest
24.8%
Employees
187
Rev per Employee
$660.0k

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy
94%
Hold
6%

Monte Rosa Therapeutics Inc Events

Past Events
NOV
16
UBS Global Biopharma Conference 2026
2 days ago
OCT
1
Special Call - Monte Rosa Therapeutics, Inc.
about 2 months ago

Financial data from Monte Rosa Therapeutics Inc

Jun '26
+/-
%
29 29
84% 84%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
18% 18%
139%
- Research and Development Expense 171 171
32% 32%
594%
-174 -174
846% 846%
-605%
- Depreciation and Amortization 8.13 8.13
3% 3%
28%
EBIT (Operating Income) EBIT -182 -182
1,316% 1,316%
-633%
Net Profit -161 -161
767% 767%
-561%

In millions USD.

Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monte Rosa Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
9 days ago
NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09...
Neutral
GlobeNewsWire
●
13 days ago
Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key  pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo; Phase 2 initiation in coronary artery disease anticipated in H1 2027 Initiation of Phase 2 study of MRT-8102 in gout expected...
Neutral
GlobeNewsWire
●
15 days ago
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the agg...
More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office United States
CEO Dr. Warmuth
Employees 187
Founded 2019
Website www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today